We found that pretreatment with the CypA inhibitor CsA alleviated BBB damage and delirium-like behavior induced by ROS production, indicating that ROS may regulate BBB permeability and delirium-like behavior via the CypA/MMP9 pathway, in which CypA is a potential therapeutic target for preventing POD. Here, MMP9 is linked to delirium.